Bluejay Diagnostics Stock Nearly Triples After U.S. Manufacturing Deal — Here’s the FDA Catch
Bluejay Diagnostics shares surged in late-morning Nasdaq trading on Tuesday after the micro-cap diagnostics company announced a U.S. manufacturing partnership for its Symphony sepsis-testing platform. The stock was up about 171% at $5.88 after touching $8.38, with volume above 61 million shares and market value still only about $5.8 million.
Company hubNASDAQ:JAY
Bluejay Diagnostics (JAY) Stock News & Analysis
Follow the latest Bluejay Diagnostics (JAY) company news, earnings coverage and investor analysis from TechStock².
Save this hub to your TS2 Signalbook account.
- Latest update
- Articles in this hub
- 1
- Last 30 days
- 0
What investors are watching
- Earnings, guidance and financial performance
- Valuation, trading activity and market sentiment
- Strategy, catalysts and company-specific risks
TechStock² Updates
